Product Name:

p38


Product Number:

ab-nk120-5

Price:

Regular price
$105.00
Regular price
Sale price
$105.00

Download Product PDF

Target Full Name: Mitogen-activated protein kinase 14

Target Alias: CSAID Binding protein 1; CSBP1; CSBP2; EXIP; MAP kinase MXI2; MAPkinase p38alpha; MAPK14; p38 ALPHA; p38 MAP kinase; p38 mitogen activated protein kinase; RK; SAPK 2A; Stress activated protein kinase 2A

Product Type Specific: p38-alpha MAPK (MAPK14) protein kinase pan-specific antibody

Antibody Code: NK120-5

Antibody Target Type: Pan-specific

Protein UniProt: Q16539

Protein SigNET: p38

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: A 20 amino acid residue Synthetic peptide patterned after the human p38

Production Method: Rabbit antiserum

Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.

Storage Buffer: Rabbit antiserum

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting, Immunoprecipitation, Immunohistochemistry

Antibody Dilution Recommended: 1:5000 (ECL) (WB), 1:250 (IP)

Antibody Potency: Very high potency. Detects a ~43 kDa protein corresponding to the molecular mass of p38 on SDS-PAGE immunoblots.

Antibody Species Reactivity: This antibody detects the target protein in the following species due to conservation of amino acid sequence: Human | Monkey | Cow | Pig | Sheep | Dog | Rabbit | Guinea pig | Rat | Mouse | Hamster | Chicken.

Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 38-43 kDa.

Antibody Specificity: Very high

Scientific Background: The MAPK (mitogen activated protein kinase) comprises a family of ubiquitous praline-directed, proteinserine/ threonine kinases which signal transduction pathways that control intracellular events including acute responses to hormones and major developmental changes in organisms (1). This super family consists of stress activated protein kinases (SAPKs); extracellular signal-regulated kinases (ERKs); and p38 kinases, each of which forms a separate pathway (2). The kinase members that populate each pathway are sequentially activated by phosphorylation. Phosphorylation at T180 and Y182 increases its phosphotransferase activity. These phospho-sites are targeted by MKK3 (MAP2K3), MKK6 (MAP2K6), and potentially also MKK4 (MAP2K4). Phosphorylation at Y323 also increases its phosphotransferase activity. It is inhibited by dual specificity phosphatases, such as DUSP1. Phosphorylation at T123 inhibits phosphotransferase activity and interaction with MKK6 and MAPKAPK2. Upon activation, p38 MAPK/SAPK2α translocates into the nucleus where it phosphorylates one or more nuclear substrates, effecting transcriptional changes and other cellular processes involved in cell growth, division, differentiation, inflammation, and death (3). Specifically p38 always acts as a pro-apoptotic factor with its activation leading to the release of cytochrome c from mitochondria and cleavage of caspase 3 and its downstream effector, PARP (4). p38 MAPK is activated by a variety of chemical stress inducers including hydrogen peroxide, heavy metals, anisomycin, sodium salicylate, LPS, and biological stress signals such as tumour necrosis factor, interleukin-1, ionizing and UV irradiation, hyperosmotic stress and chemotherapeutic drugs (5). As a result, p38 alpha has been widely validated as a target for inflammatory disease including rheumatoid arthritis, COPD and psoriasis (6) and has also been implicated in cancer, CNS and diabetes (7). Its many substrates include the transcription regulators ATF2, MEF2C, and MAX; the cell cycle regulator CDC25B; and p53, which indicates that p38a plays a role in stress-related transcription and in cell cycle regulation, as well as in the genotoxic stress response. It is a key player in the maintenance of hematopoiesis homeostasis, as it balances both proliferative and growth inhibitory signals from growth factors/cytokines that regulate hematopoiesis. Alterations in this controlled balance could result in either overproduction or depletion of myelosuppressive cytokines, which could lead to the development of various types of bone marrow failures. p38a may be also involved in drug resistance development of acute myeloid leukemias. This description may include information annotated by UniProt and/or Google AI.